[go: up one dir, main page]

WO2000041463A3 - Nouveau traitement - Google Patents

Nouveau traitement Download PDF

Info

Publication number
WO2000041463A3
WO2000041463A3 PCT/EP1999/010295 EP9910295W WO0041463A3 WO 2000041463 A3 WO2000041463 A3 WO 2000041463A3 EP 9910295 W EP9910295 W EP 9910295W WO 0041463 A3 WO0041463 A3 WO 0041463A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
vaccine
combination
antiviral agents
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/010295
Other languages
English (en)
Other versions
WO2000041463A2 (fr
Inventor
Gillian Frances Atkinson
Ronald James Boon
Pierre G Vandepapeliere
Martine Anne Cecil Wettendorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002359110A priority Critical patent/CA2359110A1/fr
Priority to JP2000593088A priority patent/JP2002534438A/ja
Priority to EP99965531A priority patent/EP1140163A2/fr
Priority to BR9916893-6A priority patent/BR9916893A/pt
Priority to HK02101211.9A priority patent/HK1041434A1/zh
Priority to PL99349347A priority patent/PL349347A1/xx
Priority to KR1020017008833A priority patent/KR20010090011A/ko
Priority to HU0105070A priority patent/HUP0105070A2/hu
Priority to AU21009/00A priority patent/AU760574B2/en
Priority to IL14418699A priority patent/IL144186A0/xx
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to NZ512890A priority patent/NZ512890A/en
Publication of WO2000041463A2 publication Critical patent/WO2000041463A2/fr
Publication of WO2000041463A3 publication Critical patent/WO2000041463A3/fr
Priority to NO20013337A priority patent/NO20013337L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention a trait à un produit pharmaceutique contenant, comme ingrédients actifs (1), un agent antiviral agissant contre le virus de l'hépatite B et (2), un vaccin convenant à la prophylaxie ou au traitement de l'infection par virus de l'hépatite B. Ces ingrédients actifs sont utilisés simultanément ou à la suite. Les composants préférés sont un analogue de nucléoside en tant qu'agent antiviral ainsi qu'un vaccin contre le virus de l'hépatite B renfermant un antigène de surface du virus de l'hépatite B.
PCT/EP1999/010295 1999-01-12 1999-12-21 Nouveau traitement Ceased WO2000041463A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU21009/00A AU760574B2 (en) 1999-01-12 1999-12-21 Novel treatment
EP99965531A EP1140163A2 (fr) 1999-01-12 1999-12-21 Nouveau traitement
BR9916893-6A BR9916893A (pt) 1999-01-12 1999-12-21 Tratamento
HK02101211.9A HK1041434A1 (zh) 1999-01-12 1999-12-21 抗病毒药物和乙型肝炎疫苗的联合
PL99349347A PL349347A1 (en) 1999-01-12 1999-12-21 Novel treatment
KR1020017008833A KR20010090011A (ko) 1999-01-12 1999-12-21 신규 처리
HU0105070A HUP0105070A2 (hu) 1999-01-12 1999-12-21 Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
CA002359110A CA2359110A1 (fr) 1999-01-12 1999-12-21 Nouveau traitement
JP2000593088A JP2002534438A (ja) 1999-01-12 1999-12-21 新規治療法
IL14418699A IL144186A0 (en) 1999-01-12 1999-12-21 Novel treatment
NZ512890A NZ512890A (en) 1999-01-12 1999-12-21 Antiviral agents including nucleoside analogues active against hepatitis B virus (HBV)
NO20013337A NO20013337L (no) 1999-01-12 2001-07-05 Ny behandling

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12
GB9900630.6 1999-01-12

Publications (2)

Publication Number Publication Date
WO2000041463A2 WO2000041463A2 (fr) 2000-07-20
WO2000041463A3 true WO2000041463A3 (fr) 2000-11-09

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/010295 Ceased WO2000041463A2 (fr) 1999-01-12 1999-12-21 Nouveau traitement

Country Status (19)

Country Link
EP (1) EP1140163A2 (fr)
JP (1) JP2002534438A (fr)
KR (1) KR20010090011A (fr)
CN (1) CN1391482A (fr)
AR (1) AR022250A1 (fr)
AU (1) AU760574B2 (fr)
BR (1) BR9916893A (fr)
CA (1) CA2359110A1 (fr)
CO (1) CO5241355A1 (fr)
CZ (1) CZ20012544A3 (fr)
HK (1) HK1041434A1 (fr)
HU (1) HUP0105070A2 (fr)
IL (1) IL144186A0 (fr)
NO (1) NO20013337L (fr)
NZ (1) NZ512890A (fr)
PL (1) PL349347A1 (fr)
TR (1) TR200102024T2 (fr)
WO (1) WO2000041463A2 (fr)
ZA (1) ZA200105690B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508927A (en) 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
ATE383375T1 (de) 2001-03-22 2008-01-15 Int Inst Cancer Immunology Inc Wti-modifiziertes peptid
WO2003028757A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
EP1447092A4 (fr) * 2001-09-28 2007-07-11 Haruo Sugiyama Methodes d'induction de lymphocytes t specifiques d'un antigene
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
DK2241325T3 (da) 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
WO2004053104A2 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
AR065504A1 (es) * 2007-02-28 2009-06-10 Ct Ingenieria Genetica Biotech Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
TWI827732B (zh) * 2018-12-24 2024-01-01 大陸商遠大賽威信生命科學（南京）有限公司 用於治療b型肝炎的藥物製劑及其製備方法和用途
AU2022255844A1 (en) * 2021-04-07 2023-11-16 Denka Company Limited Adjuvant activity enhancer and adjuvant composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374A2 (fr) * 1989-07-25 1991-02-27 Smithkline Biologicals S.A. Antigènes ainsi que les méthodes pour leur préparation
WO1999045957A2 (fr) * 1998-03-09 1999-09-16 Smithkline Beecham Biologicals S.A. Compositions de vaccins combines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374A2 (fr) * 1989-07-25 1991-02-27 Smithkline Biologicals S.A. Antigènes ainsi que les méthodes pour leur préparation
WO1999045957A2 (fr) * 1998-03-09 1999-09-16 Smithkline Beecham Biologicals S.A. Compositions de vaccins combines

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERENGUER M ET AL: "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies", PROCEEDINGS ASSOCIATION OF AMERICAN PHYSICIANS, vol. 110, no. 2, March 1998 (1998-03-01), pages 98 - 112, XP000909240 *
BONI C ET AL: "Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B [see comments].", JOURNAL OF CLINICAL INVESTIGATION, (1998 SEP 1) 102 (5) 968-75., XP000909082 *
GROB P J: "Hepatitis B: virus, pathogenesis and treatment", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 1001, November 1998 (1998-11-01), pages S11 - S16, XP004150417, ISSN: 0264-410X *
MOLLOY P J ET AL: "Combined interferon, famciclovir and GM-CSF treatment of HBV infection in an individual with periarteritis nodosa.", HEPATO-GASTROENTEROLOGY, (1999 JUL-AUG) 46 (28) 2529-31., XP000909277 *
PIANKO S. ET AL: "Chronic hepatitis B: New therapies on the horizon?.", LANCET, (13 NOV 1999) 354/9191 (1662-1663)., XP000906960 *
RUDD, JENNIFER N. (1) ET AL: "Possible role for hepatitis B vaccine after lamivudine rescue for severe acute hepatitis B.", GASTROENTEROLOGY, (APRIL, 1999) VOL. 116, NO. 4 PART 2, PP. A1268. MEETING INFO.: DIGESTIVE DISEASE WEEK AND THE 100TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION ORLANDO, FLORIDA, USA MAY 16-19, 1999 AMERICAN GASTROENTEROLOGICAL A, XP000909262 *
SUK-FONG LOK A.: "Hepatitis B infection: Pathogenesis and management.", JOURNAL OF HEPATOLOGY, SUPPLEMENT, (2000) 32/1 (89-97)., XP000909278 *
VALDEZ H ET AL: "Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.", AIDS, (2000 JAN 7) 14 (1) 11-21., XP000909260 *

Also Published As

Publication number Publication date
NO20013337L (no) 2001-08-17
NZ512890A (en) 2003-09-26
CA2359110A1 (fr) 2000-07-20
AU760574B2 (en) 2003-05-15
HUP0105070A2 (hu) 2002-04-29
HK1041434A1 (zh) 2002-07-12
AR022250A1 (es) 2002-09-04
CO5241355A1 (es) 2003-01-31
PL349347A1 (en) 2002-07-15
CZ20012544A3 (cs) 2002-01-16
BR9916893A (pt) 2001-11-20
JP2002534438A (ja) 2002-10-15
EP1140163A2 (fr) 2001-10-10
IL144186A0 (en) 2002-05-23
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (fr) 2000-07-20
KR20010090011A (ko) 2001-10-17
TR200102024T2 (tr) 2001-12-21
ZA200105690B (en) 2002-09-25
CN1391482A (zh) 2003-01-15
AU2100900A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
RS20120201A3 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
CA2253490A1 (fr) Utilisation d'il-12 ifn-.alpha. pour le traitement de maladies infectieuses
DE60030293D1 (de) Harnstoffsubstituierte imidazochinoline
BR0111195A (pt) Uso de b-l-2'-desoxi-nucleosìdeos no tratamento de infecção por vìrus de hepatite delta
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
CA2434386A1 (fr) Derives de nucleoside servant d'inhibiteurs de l'arn polymerase virale arn dependante
HK1041434A1 (zh) 抗病毒药物和乙型肝炎疫苗的联合
PL344223A1 (en) Compositions for the treatment of hiv and other viral infections
HUP0300121A3 (en) Macrocyclic peptides active against the hepatitis c virus, process for preparation and pharmaceutical compositions containing them
AU1262001A (en) Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
WO2003051306A3 (fr) Nucleosides de n4-acylcytosine-1,3-dioxolane destines au traitement d'infections virales
WO2002092006A3 (fr) Composes a base d'acides nucleiques et procedes d'utilisation associes
WO2001010456A3 (fr) Peptides bloquant les infections virales et procedes d'utilisation correspondants
GB0029936D0 (en) A pharmaceutical formulation suitable for the treatment of hepititis B, hepititis C and other viral infections of the liver and a process for its preparation
EA200100494A3 (ru) Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гипатита-b
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
ZA991029B (en) Composition and methods for treatment of hiv infections.
HUP0100087A3 (en) Nucleosides analogues, the use thereof for producing medicaments useful against retroviral infections and hepatitis b virus and the same medicaments
WO1999051256A3 (fr) Utilisation de l-glu-l-trp pour le traitement d'une infection par vih
HK1041444A1 (zh) 用於治療hiv感染的包含peg-天冬酰胺酶的藥物組合物
DE60016044D1 (de) Eisenchelator enthaltende antivirale pharmazeutische zusammensetzungen
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
WO2004064784A3 (fr) Preparation et methode de prevention ou de traitement d'une infection virale
TNSN03066A1 (en) Natural antibodies active against hiv virus

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99816471.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2000 593088

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 144186

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999965531

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2359110

Country of ref document: CA

Ref document number: 2359110

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 21009/00

Country of ref document: AU

Ref document number: IN/PCT/2001/969/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 512890

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020017008833

Country of ref document: KR

Ref document number: PA/a/2001/007112

Country of ref document: MX

Ref document number: PV2001-2544

Country of ref document: CZ

Ref document number: 2001/02024

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 09869998

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999965531

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017008833

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-2544

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 21009/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999965531

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017008833

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-2544

Country of ref document: CZ